UK’s Milner Therapeutics Institute has launched the first functional genomics screening laboratory (FGSL) in collaboration with AstraZeneca, the University of Cambridge and the Medical Research Council. The lab, located in Cambridge, will offer arrayed CRISPR screening to explore the link between genes and diseases, and to identify potential targets for drug discovery across chronic conditions, such as cardiovascular and metabolic diseases. The first projects at the FGSL will study liver regeneration and inflammatory bowel disease.
400+ SAP NetWeaver Devices Vulnerable to 0-Day Attacks that Exploited in the Wild
Shadow Servers have identified 454 vulnerable SAP NetWeaver systems affected by a critical zero-day flaw, CVE-2025-31324, allowing unauthenticated file uploads and potential system compromise. Discovered
